JBJakkrapatara BoonruangMDSlidesetHIVRSVAsia-Pacific HIV Clinical Forum 2022Clinical Case (Focused on Prevention) - Jakkrapatara Boonruang, MDView Slideset
V(TViet (Mason) TrinhB.S.SlidesetHIVAsia-Pacific HIV Prevention Meeting 2022Con Standpoint of the Debate - Viet (Mason) Trinh, B.S.View Slideset
SlidesetHIVAsia-Pacific HIV Prevention Meeting 2022CON Perspective - Debate: When Available, Long-Acting Cabotegravir Should be the First Option for PrEP in Public Health Setting - Viet (Mason) TrinhView Slideset
GEGGlenda E. GrayMBBCH, FCPaeds (SA), DScSlidesetHIVAsia-Pacific HIV Prevention Meeting 2022Update on HIV Vaccine and Monoclonal AntibodyView Slideset
RSRobin SchaeferBA, MPH, PhDSlidesetHIVAsia-Pacific HIV Prevention Meeting 2022Long-Acting PrEP in Low- And Middle-Income CountriesView Slideset
AAAlejandro AfaniMDSlidesetHIVMexican HIV Clinical Forum 2022Initial Therapy. Two or Three Drugs - Alejandro AfaniView Slideset
NFNicole FinkelsteinSlidesetHIVMexican HIV Clinical Forum 2022PrEP - The Mexican Experience - Nicole FinkelsteinView Slideset
LAQLuis Adrián QuirozSlidesetHIVMexican HIV Clinical Forum 2022Client Experience With Therapeutic HIV Prevention Options - Luis Adrián QuirozView Slideset
ALIAlvaro López IñiguezMDSlidesetHIVMexican HIV Clinical Forum 2022Mexican Treatment Guidelines - Similarities and Differences - Alvaro López IñiguezView Slideset
JLBJosé Luis BlancoMD, PhDSlidesetHIVMexican HIV Clinical Forum 2022Resistance Considerations in Choice of Regimen - José Luis Blanco ArévaloView Slideset
ATAlice TsengB.Sc.Phm., PharmD, FCSHP, AAHIVPSlidesetHIVMexican HIV Clinical Forum 2022Pharmacological Considerations in Choice of Regimen - Alice TsengView Slideset
LESLuis E. Soto-RamírezMDSlidesetHIVMexican HIV Clinical Forum 2022Considerations in Switching to Newer Regimens in Patients Suppressed on Older Drugs - Luis E. Soto-RamírezView Slideset
